Cyclin E expression in operable breast cancer quantified using real-time RT-PCR: A comparative study with immunostaining

Japanese Journal of Clinical Oncology

Volumn 36, Issue 3, 2006, Pages 142-149

  Potemski, Piotr ^a   Pluciennik, Elzbieta ^a   Bednarek, Andrzej K ^a   Kusinska, Renata ^a   Jesionek Kupnicka, Dorota ^a   Pasz Walczak, Grazyna ^a   Watala, Cezary ^a   Kordek, Radzislaw ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Breast neoplasms; Cyclin E; Immunochemistry; Prognosis; Reverse transcription PCR

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; BETA 2 MICROGLOBULIN; CYCLIN E; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; INTRADUCTAL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; PROBABILITY; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RELIABILITY; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; COMBINED MODALITY THERAPY; CYCLIN E; FEMALE; HUMANS; IMMUNOCHEMISTRY; LYMPHATIC METASTASIS; MASTECTOMY, RADICAL; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS;

EID: 33645874764     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyi246     Document Type: Article

References (29)

1. Senn HJ, Thurlimann B, Goldhirsch A, Wood WC, Gelber RD, Coates AS. Comments on the St. Gallen Consensus 2003 on the Primary Therapy of Early Breast Cancer. Breast 2003;12:569-82.
2. Sherr CJ. Cancer cell cycle. Science 1996;274:1672-7.
3. Sherr CJ. The Pezcoller Lecture: Cancer cell cycles revisited. Cancer Res 2000;60:3689-95.
4. Donnellan R, Chetty R. Cyclin E in human cancers. FASEB J 1999; 13:773-80.
5. Nielsen NH, Arnerlov C, Emdin SO, Landberg G. Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status. Br J Cancer 1996;74:874-80.
6. Scott KA, Walker RA. Lack of cyclin E immunoreactivity in non-malignant breast and association with proliferation in breast cancer. Br J Cancer 1997;76:1288-92.
7. Foulkes WD, Brunet JS, Stefansson IM, Straume O, Chappuis PO, Begin LR, et al. The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res 2004;64:830-5.
8. Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, et al. Cyclin E and survival in patients with breast cancer. N Engl J Med 2002;347:1566-75.
9. Hedberg Y, Ljungberg B, Roos G, Landberg G. Expression of cyclin D1, D3, E, and p27 in human renal cell carcinoma analyzed by tissue microrray. Br J Cancer 2003;88:1417-23.
10. Span PN, Tjan-Heijnen VC, Manders P, Beex LV, Sweep CG. Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer. Oncogene 2003;22:4898-904.
11. Donnellan R, Kleinschmidt I, Chetty R. Cyclin E immunoexpression in breast ductal carcinoma: Pathologic correlations and prognostic implications. Hum Pathol 2001;32:89-94.
12. Porter PL, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, et al. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 1997;3:222-5.
13. Han S, Park K, Bae BN, Kim KH, Kim HJ, Kim YD, et al. Prognostic implication of cyclin E expression and its relationship with cyclin D1 and p27Kip1 expression on tissue microarrays of node negative breast cancer. J Surg Oncol 2003;83:241-7.
14. Lindahl T, Landberg G, Ahlgren J, Nordgren H, Norberg T, Klaar S, et al. Overexpression of cyclin E protein is associated with specific mutation types in the p53 gene and poor survival in human breast cancer. Carcinogenesis 2004;25:375-80.
15. Nielsen NH, Arnerlov C, Cajander S, Landberg G. Cyclin E expression and proliferation in breast cancer. Anal Cell Pathol 1998;17:177-88.
16. Kuhling H, Alm P, Olsson H, Ferno M, Baldetorp B, Parwaresch R, et al. Expression of cyclins E, A, and B, and prognosis in lymph node-negative breast cancer. J Pathol 2003;199:424-31.
17. Rudolph P, Kuhling H, Alm P, Ferno M, Baldetorp B, Olsson H, et al. Differential prognostic impact of the cyclins E and B in premenopausal and postmenopausal women with lymph node-negative breast cancer. Int J Cancer 2003;105:674-80.
18. Bukholm IR, Bukholm G, Nesland JM. Over-expression of cyclin A is highly associated with early relapse and reduced survival in patients with primary breast carcinomas. Int J Cancer 2001;93:283-7.
19. Engels WR. Contributing software to the Internet: The Amplify program. Trends Biochem Sci 1993;18:448-50.
20. Mitas M, Mikhitarian K, Walters C, Baron PL, Elliott BM, Brothers TE, et al. Quantitative real-time RT-PCR detection of breast cancer micrometastasis using a multigene marker panel. Int J Cancer 2001;93:162-71.
21. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402-8.
22. McCarty KS Jr, Miller LS, Cox EB, Konrath J, McCarty KS Sr. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 1985;109:716-21.
23. Tsuda H, Bandera CA, Birrer MJ, Hashiguchi Y, Berkowitz RS, Mok SC. Cyclin E amplification and overexpression in clear cell adenocarcinoma of the ovary. Oncology 2004;67:291-9.
24. Muller-Tidow C, Metzger R, Kugler K, Diederichs S, Idos G, Thomas M, et al. Cyclin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage non-small cell lung cancer. Cancer Res 2001;61:647-53.
25. Porter DC, Zhang N, Danes C, McGahren MJ, Harwell RM, Faruki S, et al. Tumor-specific proteolytic processing of cyclin E generates hyperactive lower-molecular-weight forms. Mol Cell Biol 2001;21:6254-69.
26. Harwell RM, Porter DC, Danes C, Keyomarsi K. Processing of cyclin E differs between normal and tumor breast cells. Cancer Res 2000;60:481-9.
27. Akli S, Keyomarsi K. Low-molecular-weight cyclin E: The missing link between biology and clinical outcome. Breast Cancer Res 2004;6:188-91.
28. Porter DC, Keyomarsi K. Novel splice variants of cyclin E with altered substrate specificity. Nucleic Acids Res 2000;28:E101-8.
29. Ekholm-Reed S, Spruck CH, Sangfelt O, vanDrogen F, Mueller-Holzner E, Widschwendter M, et al. Mutation of hCDC4 leads to cell cycle deregulation of cyclin E in cancer. Cancer Res 2004;64:795-800.